Home LiteratureArticle Details
PMID: 22891275 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4(+) Th17 cells.

The Journal of experimental medicine ·Vol. 209 ·No. 9 ·2012-08-27 ·Pages 1595-609

Coccia M, Harrison OJ, Schiering C, Asquith MJ, Becher B, Powrie F, Maloy KJ

Abstract

Although very high levels of interleukin (IL)-1β are present in the intestines of patients suffering from inflammatory bowel diseases (IBD), little is known about the contribution of IL-1β to intestinal pathology. Here, we used two complementary models of chronic intestinal inflammation to address the role of IL-1β in driving innate and adaptive pathology in the intestine. We show that IL-1β promotes innate immune pathology in Helicobacter hepaticus-triggered intestinal inflammation by augmenting the recruitment of granulocytes and the accumulation and activation of innate lymphoid cells (ILCs). Using a T cell transfer colitis model, we demonstrate a key role for T cell-specific IL-1 receptor (IL-1R) signals in the accumulation and survival of pathogenic CD4(+) T cells in the colon. Furthermore, we show that IL-1β promotes Th17 responses from CD4(+) T cells and ILCs in the intestine, and we describe synergistic interactions between IL-1β and IL-23 signals that sustain innate and adaptive inflammatory responses in the gut. These data identify multiple mechanisms through which IL-1β promotes intestinal pathology and suggest that targeting IL-1β may represent a useful therapeutic approach in IBD.

MeSH Terms
Animals CD5 Antigens/metabolism Cell Survival Colitis/immunology,metabolism,microbiology Colon/immunology,microbiology,pathology Granulocytes/immunology Helicobacter Infections/immunology,metabolism,pathology Helicobacter hepaticus/pathogenicity Immunity, Innate Interleukin-17/metabolism Interleukin-1beta/metabolism Interleukin-23/metabolism Lymphocytes/immunology Mice Mice, Inbred C57BL Receptors, Interleukin-1/metabolism Receptors, Interleukin-1 Type I/metabolism Th17 Cells/immunology,metabolism
Chemicals
CD5 Antigens Interleukin-17 Interleukin-1beta Interleukin-23 Receptors, Interleukin-1 Receptors, Interleukin-1 Type I
Authors & Affiliations
7 authors, click to expand affiliations / ORCID
Coccia Margherita
Sir William Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, England, UK.
Harrison Oliver J
Schiering Chris
Asquith Mark J
Becher Burkhard
Powrie Fiona
Maloy Kevin J
References (73)
73 references, click to expand
  1. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice.
    Clin Immunol. 2004 Jan;110(1):55-62 PMID: 14962796
  2. Phenotypically distinct subsets of CD4+ T cells induce or protect from chronic intestinal inflammation in C. B-17 scid mice.
    Int Immunol. 1993 Nov;5(11):1461-71 PMID: 7903159
  3. Interleukin-23 drives innate and T cell-mediated intestinal inflammation.
    J Exp Med. 2006 Oct 30;203(11):2473-83 PMID: 17030949
  4. Enhanced production of interleukin 1-beta by mononuclear cells isolated from mucosa with active ulcerative colitis of Crohn's disease.
    Gut. 1989 Jun;30(6):835-8 PMID: 2787769
  5. Interleukins 1beta and 6 but not transforming growth factor-beta are essential for the differentiation of interleukin 17-producing human T helper cells.
    Nat Immunol. 2007 Sep;8(9):942-9 PMID: 17676045
  6. The IL-1 family: regulators of immunity.
    Nat Rev Immunol. 2010 Feb;10(2):89-102 PMID: 20081871
  7. Identification of a genetic locus controlling bacteria-driven colitis and associated cancer through effects on innate inflammation.
    J Exp Med. 2012 Jul 2;209(7):1309-24 PMID: 22734048
  8. A protective function for interleukin 17A in T cell-mediated intestinal inflammation.
    Nat Immunol. 2009 Jun;10(6):603-9 PMID: 19448631
  9. Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue.
    Immunity. 2010 Jun 25;32(6):803-14 PMID: 20620944
  10. An autoinflammatory disease due to homozygous deletion of the IL1RN locus.
    N Engl J Med. 2009 Jun 4;360(23):2438-44 PMID: 19494219
  11. Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production.
    Nature. 2008 Nov 13;456(7219):264-8 PMID: 18849965
  12. The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease.
    J Immunol. 2008 Feb 1;180(3):1886-94 PMID: 18209086
  13. IL-1 family members and STAT activators induce cytokine production by Th2, Th17, and Th1 cells.
    Proc Natl Acad Sci U S A. 2009 Aug 11;106(32):13463-8 PMID: 19666510
  14. A novel heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes.
    Nature. 1992 Apr 30;356(6372):768-74 PMID: 1574116
  15. Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology.
    Nature. 2010 Apr 29;464(7293):1371-5 PMID: 20393462
  16. Interleukin 1 (IL-1) gene expression, synthesis, and effect of specific IL-1 receptor blockade in rabbit immune complex colitis.
    J Clin Invest. 1990 Sep;86(3):972-80 PMID: 2168444
  17. IL-23 plays a key role in Helicobacter hepaticus-induced T cell-dependent colitis.
    J Exp Med. 2006 Oct 30;203(11):2485-94 PMID: 17030948
  18. Imbalance between interleukin-1 agonists and antagonists: relationship to severity of inflammatory bowel disease.
    Clin Exp Immunol. 2004 Nov;138(2):323-9 PMID: 15498044
  19. Th17 and regulatory T cells in mediating and restraining inflammation.
    Cell. 2010 Mar 19;140(6):845-58 PMID: 20303875
  20. A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses.
    Immunity. 2009 Jun 19;30(6):860-74 PMID: 19501001
  21. The inflammasomes: guardians of the body.
    Annu Rev Immunol. 2009;27:229-65 PMID: 19302040
  22. CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner.
    Science. 2009 Nov 13;326(5955):986-91 PMID: 19797626
  23. Future biologic targets for IBD: potentials and pitfalls.
    Nat Rev Gastroenterol Hepatol. 2010 Feb;7(2):110-7 PMID: 20134493
  24. Enhanced Th1 and Th17 responses and arthritis severity in mice with a deficiency of myeloid cell-specific interleukin-1 receptor antagonist.
    Arthritis Rheum. 2010 Feb;62(2):452-62 PMID: 20112392
  25. Upregulation of interleukin-12 and -17 in active inflammatory bowel disease.
    Scand J Gastroenterol. 2003 Feb;38(2):180-5 PMID: 12678335
  26. Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity.
    Immunity. 2009 Aug 21;31(2):331-41 PMID: 19682929
  27. IL-1 regulates in vivo C-X-C chemokine induction and neutrophil sequestration following endotoxemia.
    J Endotoxin Res. 2002;8(1):59-67 PMID: 11981446
  28. Biologic basis for interleukin-1 in disease.
    Blood. 1996 Mar 15;87(6):2095-147 PMID: 8630372
  29. Mucosal imbalance of IL-1 and IL-1 receptor antagonist in inflammatory bowel disease. A novel mechanism of chronic intestinal inflammation.
    J Immunol. 1995 Mar 1;154(5):2434-40 PMID: 7868909
  30. IL-1 acts directly on CD4 T cells to enhance their antigen-driven expansion and differentiation.
    Proc Natl Acad Sci U S A. 2009 Apr 28;106(17):7119-24 PMID: 19359475
  31. Inflammatory bowel disease: clinical aspects and established and evolving therapies.
    Lancet. 2007 May 12;369(9573):1641-57 PMID: 17499606
  32. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.
    Clin Exp Immunol. 1993 Oct;94(1):174-81 PMID: 8403503
  33. Pathogenic and protective roles of MyD88 in leukocytes and epithelial cells in mouse models of inflammatory bowel disease.
    Gastroenterology. 2010 Aug;139(2):519-29, 529.e1-2 PMID: 20433840
  34. RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F.
    Gastroenterology. 2009 Jan;136(1):257-67 PMID: 18992745
  35. Regulatory T cells suppress systemic and mucosal immune activation to control intestinal inflammation.
    Immunol Rev. 2006 Aug;212:256-71 PMID: 16903919
  36. Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity.
    Immunity. 2009 Jun 19;30(6):875-87 PMID: 19501000
  37. A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis.
    J Exp Med. 2006 Jul 10;203(7):1685-91 PMID: 16818675
  38. MyD88-dependent pathway in T cells directly modulates the expansion of colitogenic CD4+ T cells in chronic colitis.
    J Immunol. 2008 Apr 15;180(8):5291-9 PMID: 18390710
  39. In vitro and in vivo characterization of Helicobacter hepaticus cytolethal distending toxin mutants.
    Infect Immun. 2004 May;72(5):2521-7 PMID: 15102759
  40. The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF.
    Nat Immunol. 2011 Jun;12(6):568-75 PMID: 21516111
  41. Increased expression of interleukin 17 in inflammatory bowel disease.
    Gut. 2003 Jan;52(1):65-70 PMID: 12477762
  42. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice.
    Gastroenterology. 1990 Mar;98(3):694-702 PMID: 1688816
  43. The S. Typhimurium effector SopE induces caspase-1 activation in stromal cells to initiate gut inflammation.
    Cell Host Microbe. 2009 Aug 20;6(2):125-36 PMID: 19683679
  44. Identity, regulation and in vivo function of gut NKp46+RORγt+ and NKp46+RORγt- lymphoid cells.
    EMBO J. 2011 Jun 17;30(14):2934-47 PMID: 21685873
  45. CD4+ CD25+ regulatory T lymphocytes inhibit microbially induced colon cancer in Rag2-deficient mice.
    Am J Pathol. 2003 Feb;162(2):691-702 PMID: 12547727
  46. Interleukin-23 drives intestinal inflammation through direct activity on T cells.
    Immunity. 2010 Aug 27;33(2):279-88 PMID: 20732640
  47. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1beta reveals intrinsic functional plasticity.
    Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10961-6 PMID: 20534450
  48. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist.
    N Engl J Med. 2009 Jun 4;360(23):2426-37 PMID: 19494218
  49. Inflammatory bowel disease.
    Annu Rev Immunol. 2010;28:573-621 PMID: 20192811
  50. Microbiota-induced IL-1β, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine.
    J Exp Med. 2012 Feb 13;209(2):251-8 PMID: 22291094
  51. Nod2 mutation in Crohn's disease potentiates NF-kappaB activity and IL-1beta processing.
    Science. 2005 Feb 4;307(5710):734-8 PMID: 15692052
  52. ATP drives lamina propria T(H)17 cell differentiation.
    Nature. 2008 Oct 9;455(7214):808-12 PMID: 18716618
  53. Crohn's disease-associated ATG16L1 polymorphism modulates pro-inflammatory cytokine responses selectively upon activation of NOD2.
    Gut. 2011 Sep;60(9):1229-35 PMID: 21406388
  54. Interleukin-23 restrains regulatory T cell activity to drive T cell-dependent colitis.
    Immunity. 2008 Apr;28(4):559-70 PMID: 18400195
  55. IL-1 pathways in inflammation and human diseases.
    Nat Rev Rheumatol. 2010 Apr;6(4):232-41 PMID: 20177398
  56. CD4+CD25+ T(R) cells suppress innate immune pathology through cytokine-dependent mechanisms.
    J Exp Med. 2003 Jan 6;197(1):111-9 PMID: 12515818
  57. A human natural killer cell subset provides an innate source of IL-22 for mucosal immunity.
    Nature. 2009 Feb 5;457(7230):722-5 PMID: 18978771
  58. Role of interleukin 1 in inflammatory bowel disease--enhanced production during active disease.
    Gut. 1990 Jun;31(6):686-9 PMID: 2379873
  59. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice.
    J Exp Med. 2000 Jan 17;191(2):313-20 PMID: 10637275
  60. Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome.
    Gastroenterology. 2010 Aug;139(2):542-52, 552.e1-3 PMID: 20398664
  61. Critical regulation of early Th17 cell differentiation by interleukin-1 signaling.
    Immunity. 2009 Apr 17;30(4):576-87 PMID: 19362022
  62. Evaluation of an interleukin-1 receptor antagonist in the rat acetic acid-induced colitis model.
    Agents Actions. 1991 Sep;34(1-2):187-90 PMID: 1838896
  63. Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease.
    Gut. 1998 Feb;42(2):214-9 PMID: 9536946
  64. RORγt drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation.
    Nat Immunol. 2011 Jun;12(6):560-7 PMID: 21516112
  65. Recombinant interleukin-1 receptor antagonist blocks the proinflammatory activity of endogenous interleukin-1 in rabbit immune colitis.
    Gastroenterology. 1992 Jul;103(1):65-71 PMID: 1535326
  66. An innately dangerous balancing act: intestinal homeostasis, inflammation, and colitis-associated cancer.
    J Exp Med. 2010 Aug 2;207(8):1573-7 PMID: 20679404
  67. IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation.
    Proc Natl Acad Sci U S A. 2001 Nov 6;98(23):13249-54 PMID: 11606779
  68. Induction of intestinal Th17 cells by segmented filamentous bacteria.
    Cell. 2009 Oct 30;139(3):485-98 PMID: 19836068
  69. Tissue interleukin 1 and interleukin-1 receptor antagonist expression in enterocolitis in resistant and susceptible rats.
    Gastroenterology. 1994 Apr;106(4):960-72 PMID: 8144001
  70. Interleukin 1 in Crohn's disease.
    Clin Exp Immunol. 1987 Mar;67(3):594-605 PMID: 3496997
  71. Human fetal lymphoid tissue-inducer cells are interleukin 17-producing precursors to RORC+ CD127+ natural killer-like cells.
    Nat Immunol. 2009 Jan;10(1):66-74 PMID: 19029905
  72. Immunological and inflammatory functions of the interleukin-1 family.
    Annu Rev Immunol. 2009;27:519-50 PMID: 19302047
  73. Generation of pathogenic T(H)17 cells in the absence of TGF-β signalling.
    Nature. 2010 Oct 21;467(7318):967-71 PMID: 20962846
Article Info
Journal
The Journal of experimental medicine
Abbr.
J Exp Med
ISSN
1540-9538
Published
2012-08-27
Epub
2012-00-13
Pages
1595-609
Language
English
Region
United States
NLM ID
2985109R
PMCID
PMC3428945
Subset
IM
Grants
Wellcome Trust · 086354 · United Kingdom
Wellcome Trust · 095688 · United Kingdom
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com